Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: A phase II study

Annals of Hematology

Volumn 89, Issue 5, 2010, Pages 475-482

  Kim, Yeo Kyeoung ^a   Sohn, Sang Kyun ^b   Lee, Jae Hoon ^c   Yang, Deok Hwan ^a   Moon, Joon Ho ^b   Ahn, Jae Sook ^a   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a,d,e  

^a Chonnam National University Medical School   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d Chonnam National University   (South Korea)

^e Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

Bortezomib; Multiple myeloma; Refractory; Relapse; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77950563131     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0856-x     Document Type: Article

References (30)

1. RA Kyle SV Rajkumar 2004 Multiple myeloma N Engl J Med 351 1860 1873 10.1056/NEJMra041875 1:CAS:528:DC%2BD2cXptFChtLk%3D 15509819 (Pubitemid 39426321)
2. DA Galton R Peto 1968 A progress report on the Medical Research Council's therapeutic trial in myelomatosis Br J Haematol 15 319 320 10.1111/j.1365-2141. 1968.tb01542.x 1:STN:280:DyaF1M%2FjtFyjtw%3D%3D 5696221
3. B Sirohi R Powles 2004 Multiple myeloma Lancet 363 875 887 10.1016/S0140-6736(04)15736-X 15031034 (Pubitemid 38368839)
4. R Alexanian B Barlogie S Tucker 1990 VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 33 86 89 10.1002/ajh.2830330203 1:STN:280:DyaK3c7ksVKquw%3D%3D 2301376 (Pubitemid 20040083)
5. B Barlogie S Jagannath KR Desikan, et al. 1999 Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 55 65 1:STN:280:DyaK1M%2FotFKjsA%3D%3D 9864146
6. D Samson E Gaminara A Newland, et al. 1989 Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma Lancet 2 882 885 10.1016/S0140-6736(89)91549-3 1:STN:280:DyaK3c%2FhtlKrsQ%3D%3D 2571813
7. B Sirohi R Powles J Mehta, et al. 1999 Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system Br J Haematol 107 656 666 10.1046/j.1365-2141.1999.01744.x 1:STN:280: DC%2BD3c%2FltVehsw%3D%3D 10583272
8. H Goldschmidt U Hegenbart M Wallmeier, et al. 1997 Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony stimulating factor in patients with multiple myeloma Br J Haematol 98 736 744 10.1046/j.1365-2141.1997.2783095.x 1:STN:280:DyaK2svntlCkuw%3D%3D 9332333
9. PG Richardson T Hideshima C Mitsiades, et al. 2007 The emerging role of novel therapies for the treatment of relapsed myeloma J Natl Compr Canc Netw 5 149 162 1:CAS:528:DC%2BD1cXmtFOru7c%3D 17335684
10. JF San Miguel R Schlag NK Khuageva, et al. 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 906 917 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K 18753647
11. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN 18032762 (Pubitemid 350146107)
12. DM Weber C Chen R Niesvizky, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 10.1056/NEJMoa070596 1:CAS:528:DC%2BD2sXhtlGis7bM 18032763 (Pubitemid 350146108)
13. PG Richardson B Barlogie J Berenson, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D 12826635 (Pubitemid 36741588)
14. S Jagannath B Barlogie J Berenson 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 165 172 10.1111/j.1365-2141.2004.05188.x 1:CAS:528:DC%2BD2cXpvFait7g%3D 15461622 (Pubitemid 39371809)
15. PG Richardson P Sonneveld M Schuster, et al. 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557 3560 10.1182/blood-2006-08-036947 1:CAS:528: DC%2BD2sXhtlarur3K 17690257 (Pubitemid 350159621)
16. LM Wang DM Weber KB Delasalle, et al. 2004 VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma Blood 104 210a
17. HE Oakervee R Popat N Curry, et al. 2005 PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol 129 755 762 10.1111/j.1365-2141. 2005.05519.x 1:CAS:528:DC%2BD2MXms1ehs7c%3D 15953001 (Pubitemid 40904525)
18. MA Dimopoulos K Zervas G Kouvatseas, et al. 2001 Thalidomide and dexamethasone combination for refractory multiple myeloma Ann Oncol 12 991 995 10.1023/A:1011132808904 1:STN:280:DC%2BD3MvnvVegsg%3D%3D 11521808 (Pubitemid 32725775)
19. DM Weber K Rankin M Gavino, et al. 2000 Thalidomide with dexamethasone for resistant multiple myeloma Blood 96 167a
20. A Palumbo L Giaccone A Bertola, et al. 2001 Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma Haematologica 86 399 403 1:CAS:528:DC%2BD3MXks1ait7w%3D 11325646 (Pubitemid 32428500)
21. R Garcia-Sanz MI Gonzalez-Fraile M Sierra C Lopez, et al. 2003 The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma Hematol J 3 43 48 10.1038/sj.thj.6200150
22. G Srkalovic P Elson B Trebisky, et al. 2002 Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma Med Oncol 19 219 226 10.1385/MO:19:4:219 1:CAS:528: DC%2BD3sXltFKruw%3D%3D 12512915 (Pubitemid 36016012)
23. PG Richardson H Briemberg S Jagannath, et al. 2006 Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J Clin Oncol 24 3113 3120 10.1200/JCO.2005.04.7779 1:CAS:528:DC%2BD28XnslKhs7c%3D 16754936 (Pubitemid 46638949)
24. BG Durie JL Harousseau JS Miguel, et al. 2006 International uniform response criteria for multiple myeloma Leukemia 20 1467 1473 10.1038/sj.leu.2404284 1:STN:280:DC%2BD28rgt1aqtA%3D%3D 16855634 (Pubitemid 44264086)
25. A Chanan-Khan P Sonneveld MW Schuster, et al. 2008 Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study J Clin Oncol 26 4784 4790 10.1200/JCO.2007.14.9641 1:CAS:528:DC%2BD1cXhtlSqsb7K 18711175
26. E Terpos E Kastritis M Roussou, et al. 2008 The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis Leukemia 22 2247 2256 10.1038/leu.2008.235 1:CAS:528:DC%2BD1cXhsFWjtb7K 18769451
27. A Palumbo MT Ambrosini G Benevolo, et al. 2007 Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Blood 109 2767 2772 1:CAS:528:DC%2BD2sXjvVynsrg%3D 17148584
28. P Musto A Falcone G Sanpaolo, et al. 2006 Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide Leuk Res 30 283 285 10.1016/j.leukres.2005.06.027 1:CAS:528: DC%2BD28XksFGhsA%3D%3D 16111749 (Pubitemid 43053223)
29. R Popat H Oakervee C Williams, et al. 2009 Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma Br J Haematol 144 887 894 10.1111/j.1365-2141.2008.07572.x 1:CAS:528:DC%2BD1MXkt12ntb8%3D 19183191
30. DE Reece GP Rodriguez C Chen, et al. 2008 Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma J Clin Oncol 26 4777 4783 10.1200/JCO.2007.14.2372 1:CAS:528: DC%2BD1cXhtlSqsb7J 18645194